JP2013533884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533884A5 JP2013533884A5 JP2013518689A JP2013518689A JP2013533884A5 JP 2013533884 A5 JP2013533884 A5 JP 2013533884A5 JP 2013518689 A JP2013518689 A JP 2013518689A JP 2013518689 A JP2013518689 A JP 2013518689A JP 2013533884 A5 JP2013533884 A5 JP 2013533884A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- halo
- cyano
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 103
- 125000005843 halogen group Chemical group 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000000464 thioxo group Chemical group S=* 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36101410P | 2010-07-02 | 2010-07-02 | |
| US61/361,014 | 2010-07-02 | ||
| PCT/US2011/042519 WO2012003271A1 (en) | 2010-07-02 | 2011-06-30 | Heterocyclic compounds and their use as inhibitors of pi3k activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533884A JP2013533884A (ja) | 2013-08-29 |
| JP2013533884A5 true JP2013533884A5 (enExample) | 2014-08-14 |
Family
ID=44307237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518689A Withdrawn JP2013533884A (ja) | 2010-07-02 | 2011-06-30 | Ｐｉ３ｋ活性阻害剤としての複素環化合物およびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130096134A1 (enExample) |
| EP (1) | EP2588469A1 (enExample) |
| JP (1) | JP2013533884A (enExample) |
| AU (1) | AU2011272850A1 (enExample) |
| CA (1) | CA2803624A1 (enExample) |
| MX (1) | MX2012015134A (enExample) |
| WO (1) | WO2012003271A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| WO2012061696A1 (en) * | 2010-11-04 | 2012-05-10 | Amgen Inc. | 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k- delta inhibitors |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| UA121539C2 (uk) | 2011-09-02 | 2020-06-25 | Інсайт Холдинґс Корпорейшн | Гетероцикліламіни як інгібітори рі3к |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| DK2834231T3 (en) * | 2012-04-04 | 2016-04-18 | Amgen Inc | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP2917216B1 (en) | 2012-11-08 | 2017-10-18 | Pfizer Inc | Heteroaromatic compounds as dopamine d1 ligands |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| AU2013364070B2 (en) | 2012-12-21 | 2016-10-27 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| TW201441216A (zh) | 2012-12-21 | 2014-11-01 | Gilead Calistoga Llc | 肌醇磷酯３－激酶的抑制劑 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| TR201806822T4 (tr) | 2013-06-14 | 2018-06-21 | Gilead Calistoga Llc | Fosfatidilinositol 3-kinaz inhibitörleri. |
| CN104418849B (zh) * | 2013-09-02 | 2020-04-21 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| SG11201610770PA (en) | 2014-07-04 | 2017-01-27 | Lupin Ltd | Quinolizinone derivatives as pi3k inhibitors |
| EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| UA122332C2 (uk) | 2015-02-27 | 2020-10-26 | Інсайт Корпорейшн | Солі інгібітора pi3k і способи їх отримання |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| DK4426434T3 (da) | 2021-11-02 | 2025-11-10 | Flare Therapeutics Inc | Pparg inverse agonists and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| RS54706B1 (sr) | 2007-03-23 | 2016-08-31 | Amgen Inc. | Heterociklična jedinjenja i njihove upotrebe |
| EP2231641B1 (en) * | 2007-12-21 | 2016-06-01 | UCB Biopharma SPRL | Quinoxaline and quinoline derivatives as kinase inhibitors |
| JP5731978B2 (ja) * | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| EP2396315B1 (en) * | 2009-02-13 | 2016-08-31 | UCB Biopharma SPRL | Quinoline derivatives as pi3k kinase inhibitors |
| WO2011058111A1 (en) * | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Aminopurine derivatives as kinase inhibitors |
| WO2011058113A1 (en) * | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| MX2012006953A (es) * | 2009-12-18 | 2012-10-09 | Amgen Inc | Compuestos heterociclicos y sus usos. |
-
2011
- 2011-06-30 MX MX2012015134A patent/MX2012015134A/es not_active Application Discontinuation
- 2011-06-30 AU AU2011272850A patent/AU2011272850A1/en not_active Abandoned
- 2011-06-30 WO PCT/US2011/042519 patent/WO2012003271A1/en not_active Ceased
- 2011-06-30 US US13/703,790 patent/US20130096134A1/en not_active Abandoned
- 2011-06-30 CA CA2803624A patent/CA2803624A1/en not_active Abandoned
- 2011-06-30 JP JP2013518689A patent/JP2013533884A/ja not_active Withdrawn
- 2011-06-30 EP EP11730846.0A patent/EP2588469A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530238A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2013530236A5 (enExample) | ||
| JP2018520161A5 (enExample) | ||
| ME02754B (me) | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme | |
| JP2017508816A5 (enExample) | ||
| HRP20140147T1 (hr) | 3-supstituirani derivati hinolina ili hinoksalina i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k) | |
| JP2017512833A5 (enExample) | ||
| JP2016518385A5 (enExample) | ||
| HRP20160350T1 (hr) | Heterociklički spojevi i njihove uporabe | |
| JP2014508753A5 (enExample) | ||
| JP2013531031A5 (enExample) | ||
| JP2015535277A5 (enExample) | ||
| JP2013525433A5 (enExample) | ||
| JP2010280669A5 (enExample) | ||
| JP2013522316A5 (enExample) | ||
| JP2015143283A5 (enExample) | ||
| JP2017511815A5 (enExample) | ||
| JP2016510758A5 (enExample) | ||
| JP2011529073A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JP2017508789A5 (enExample) | ||
| JP2013530239A5 (enExample) | ||
| JP2017537940A5 (enExample) |